Evaluation of cure for COVID-19 still awaited
RESULTS of the evaluation of the possible cure for COVID-19, specifically those suffering from mild symptoms of the virus infection submitted by a Pangasinan inventor by the Philippine Council for Health Research and Development (PCHRD) are still awaited.
This was disclosed by Jaime Imbat, owner of JPI Enterprise, the developer of an all-organic medicine he tentatively called Sonyas Plems, that he submitted to the provincial and regional offices of the Department of Science and Technology (DOST).
Noting that COVID-19 is airborne which makes it more dangerous, Imbat said a cheaper and safer alternative cure to the coronavirus using only indigenous plants readily available in Pangasinan has become imperative.
Sonyas Plems, he said, not only constitutes extracts of Lagundi but also from other plants known in the past for their high medicinal values.
Imbat noted that the DOST and the University of the Philippines are jointly developing possible COVID-19 medicine from Lagundi, which he said, constitutes only one percent of Sonyas Plems.
According to Imbat, Sonyas Plems can prevent infection or cure patients with
mild and severe symptoms of COVID-19 by loosening the hardened phlegm in the
throat caused by the coronavirus, allowing a patient to breath easily.
He said he has not received any reaction from the council since he submitted his project more than a month ago and will consider seeking the help of President Duterte to fast-track the evaluation so his invention can help slow down COVID-19 contagion. (Leonardo Micua)
Share your Comments or Reactions
Powered by Facebook Comments
